Développement des biosimilaires de l’insuline : exemple de l’insuline glargine LY2963016
Jean‐Jacques Altman, Imane Benabbad(Eli Lilly (United States)), Nicolas Chevalier(Inserm), Brigitte Delemer(Centre Hospitalier Universitaire de Reims), F. Travert(Hôpital Bichat-Claude-Bernard)
Cited by 1
Related Papers
Human Health and Ocean Pollution
|Annals of Global Health|2020|751
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
|The Lancet|2023|676
Ketoconazole in Cushing's Disease: Is It Worth a Try?
|The Journal of Clinical Endocrinology & Metabolism|2014|288
Bisphenol A: An endocrine and metabolic disruptor
|Annales d Endocrinologie|2013|278
Obesity II: Establishing causal links between chemical exposures and obesity
|Biochemical Pharmacology|2022|197